Quality of Life in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Improves after Minimal Residual Disease-Guided Treatment with Ibrutinib Plus Venetoclax
Laura Eurelings(Albert Schweitzer Ziekenhuis), Mark‐David Levin(Albert Schweitzer Hospital), Henrik Frederiksen(University of Southern Denmark), Rogier Mous(University Medical Center Utrecht), Mattias Mattsson(Uppsala University Hospital), Christian Brieghel(Copenhagen University Hospital), Emelie Curovic Rotbain(Copenhagen University Hospital), Claudia A.M. Stege(Amsterdam University Medical Centers), Mar Bellido(University Medical Center Groningen), Sabina Kersting(Haga Hospital), Kazem Nasserinejad(Erasmus MC Cancer Institute), Christian Bjørn Poulsen(University of Copenhagen), Carsten Utoft Niemann(University of Copenhagen), G.J. Veldhuis(St. Antonius Ziekenhuis), Arnon P. Kater(Amsterdam University Medical Centers), Ann Janssens, Hoa Tran(Akershus University Hospital), Ellen C. Dompeling(Isala), Juha Ranti(Turku University Hospital), Lisbeth Enggaard(Copenhagen University Hospital), Ida Schjoedt(Copenhagen University Hospital), Lina van der Straten(Erasmus MC)
Cited by 1
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568